The donepezil market was valued at $0.9 billion in 2023, and is projected to reach $1.1 billion by 2033, growing at a CAGR of 1.9% from 2024 to 2033.
Donepezil is a medication primarily used to treat symptoms of Alzheimer's disease and other forms of dementia. It belongs to a class of drugs known as acetylcholinesterase inhibitors, which work by increasing the levels of acetylcholine, a neurotransmitter involved in memory and cognitive function. Donepezil does not cure Alzheimer's, but it can help slow the progression of symptoms such as memory loss, confusion, and difficulties in thinking or reasoning, especially in the early to moderate stages of the disease.
The growth of the global donepezil market is driven by alarming rise in the prevalence of Alzheimer's and other dementias. According to a study published by the BrightFocus Foundation - a non-profit organization that funds exceptional scientific research worldwide to defeat Alzheimer’s disease, macular degeneration, and glaucoma - approximately 55 million individuals are estimated to be suffering from Alzheimer’s or other dementias. This number is anticipated to rise to 152 million by 2050. In addition, increase in awareness about Alzheimer’s disease and improved diagnostic capabilities lead to higher rates of diagnosis, contributing to the market growth. Moreover, surge in geriatric population acts as the key driving force of the global market.
This is attributed to the fact that as people age, the brain naturally undergoes neurodegeneration, characterized by the loss of neurons and synapses, which is associated with cognitive decline and Alzheimer’s. As per the World Health Organization, the number of people aged 60 years and older was 1 billion in 2019. This number is estimated to increase to 1.4 billion by 2030 and 2.1 billion by 2050. Furthermore, the introduction of generic versions of Donepezil offers more affordable treatment options, expanding the market reach and increasing patient adherence.
However, common side effects of Donepezil, such as nausea, diarrhea, insomnia, and muscle cramps, can lead to treatment discontinuation or non-adherence among patients, thus impacting the market growth. In addition, the development of alternative treatments for Alzheimer's, including other medications and non-pharmacological interventions, can limit the demand for donepezil. On the contrary, ongoing research into Alzheimer's treatments and the efficacy of donepezil spurs the market interest, as new formulations or combinations with other therapies may enhance treatment outcomes. Such developments are expected to offer lucrative opportunities for the expansion of the global market during the forecast period.
The global donepezil market is segmented into dosage strength, route of administration, distribution channel, and region. On the basis of the dosage strength, the market is categorized into 5mg, 10mg, and 23mg. By route of administration, it is classified into oral and transdermal. Depending on distribution channel, it is segregated into hospital pharmacies, drug stores & retail pharmacies, and online providers. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
On the basis of route of administration, the oral segment is anticipated to exhibit the highest growth during the forecast period.
Depending on distribution channel, the drug stores & retail pharmacies segment held a substantial portion of the donepezil market share.
Region wise, North America is poised to maintain its leadership in the donepezil market in the coming years.
Donepezil is a medication primarily used to treat symptoms of Alzheimer's disease and other forms of dementia. It belongs to a class of drugs known as acetylcholinesterase inhibitors, which work by increasing the levels of acetylcholine, a neurotransmitter involved in memory and cognitive function. Donepezil does not cure Alzheimer's, but it can help slow the progression of symptoms such as memory loss, confusion, and difficulties in thinking or reasoning, especially in the early to moderate stages of the disease.
The growth of the global donepezil market is driven by alarming rise in the prevalence of Alzheimer's and other dementias. According to a study published by the BrightFocus Foundation - a non-profit organization that funds exceptional scientific research worldwide to defeat Alzheimer’s disease, macular degeneration, and glaucoma - approximately 55 million individuals are estimated to be suffering from Alzheimer’s or other dementias. This number is anticipated to rise to 152 million by 2050. In addition, increase in awareness about Alzheimer’s disease and improved diagnostic capabilities lead to higher rates of diagnosis, contributing to the market growth. Moreover, surge in geriatric population acts as the key driving force of the global market.
This is attributed to the fact that as people age, the brain naturally undergoes neurodegeneration, characterized by the loss of neurons and synapses, which is associated with cognitive decline and Alzheimer’s. As per the World Health Organization, the number of people aged 60 years and older was 1 billion in 2019. This number is estimated to increase to 1.4 billion by 2030 and 2.1 billion by 2050. Furthermore, the introduction of generic versions of Donepezil offers more affordable treatment options, expanding the market reach and increasing patient adherence.
However, common side effects of Donepezil, such as nausea, diarrhea, insomnia, and muscle cramps, can lead to treatment discontinuation or non-adherence among patients, thus impacting the market growth. In addition, the development of alternative treatments for Alzheimer's, including other medications and non-pharmacological interventions, can limit the demand for donepezil. On the contrary, ongoing research into Alzheimer's treatments and the efficacy of donepezil spurs the market interest, as new formulations or combinations with other therapies may enhance treatment outcomes. Such developments are expected to offer lucrative opportunities for the expansion of the global market during the forecast period.
The global donepezil market is segmented into dosage strength, route of administration, distribution channel, and region. On the basis of the dosage strength, the market is categorized into 5mg, 10mg, and 23mg. By route of administration, it is classified into oral and transdermal. Depending on distribution channel, it is segregated into hospital pharmacies, drug stores & retail pharmacies, and online providers. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Key Findings
By dosage strength, the 5 mg segment is expected to dominate the market from 2024 to 2033.On the basis of route of administration, the oral segment is anticipated to exhibit the highest growth during the forecast period.
Depending on distribution channel, the drug stores & retail pharmacies segment held a substantial portion of the donepezil market share.
Region wise, North America is poised to maintain its leadership in the donepezil market in the coming years.
Competition Analysis
Competitive analysis and profiles of the major players in the global donepezil market include Eisai Co., Ltd., Alteus, Corium, LLC., DD Pharmaceuticals Pvt Ltd, Intas Pharmaceuticals Ltd., Dr. Reddy’s Laboratories Ltd., Sun Pharmaceutical, Jiangsu Hansoh Pharmaceutical Group Co., Ltd., Cipla, and Alkem. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships to sustain the intense competition and gain a strong foothold in the global market.Additional benefits you will get with this purchase are:
- Quarterly Update* (with the purchase of an enterprise license)
- 5 additional Company Profiles, pre- or post-purchase, as a free update.
- Free Updated Version (once released) with the purchase of an enterprise user license.
- 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
- 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
- Free data Pack on the Enterprise User License. (Excel version of the report)
- Free Updated report if the report is 6-12 months old or older.
- 24-hour priority response*
- Free Industry updates and white papers.
Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)
- Regulatory Guidelines
- Additional company profiles with specific to client's interest
- Additional country or region analysis- market size and forecast
- Expanded list for Company Profiles
- Historic market data
- Key player details (including location, contact details, supplier/vendor network etc. in excel format)
Key Market Segments
By Dosage Strength
- 5mg
- 10mg
- 23mg
By Route Of Administeration
- Oral
- Transdermal
By Distribution Channel
- Hospital Pharmacies
- Drug stores and Retail Pharmacies
- Online Providers
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
Key Market Players
- Eisai Co., Ltd.
- Alteus
- Corium, LLC.
- DD Pharmaceuticals Pvt Ltd
- Intas Pharmaceuticals Ltd.
- Dr. Reddy’s Laboratories Ltd.
- Sun Pharmaceutical
- Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
- Cipla
- Alkem
Please note:
- Online Access price format is valid for 60 days access. Printing is not enabled.
- PDF Single and Enterprise price formats enable printing.
Table of Contents
CHAPTER 1: INTRODUCTION
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET LANDSCAPE
CHAPTER 4: DONEPEZIL MARKET, BY DOSAGE STRENGTH
CHAPTER 5: DONEPEZIL MARKET, BY ROUTE OF ADMINISTERATION
CHAPTER 6: DONEPEZIL MARKET, BY DISTRIBUTION CHANNEL
CHAPTER 7: DONEPEZIL MARKET, BY REGION
CHAPTER 8: COMPETITIVE LANDSCAPE
CHAPTER 9: COMPANY PROFILES
LIST OF TABLES
LIST OF FIGURES
Companies Mentioned
Eisai Co., Ltd.- Alteus
- Corium, LLC.
- DD Pharmaceuticals Pvt Ltd
- Intas Pharmaceuticals Ltd.
- Dr. Reddy’s Laboratories Ltd.
- Sun Pharmaceutical
- Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
- Cipla
- Alkem
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 230 |
| Published | September 2024 |
| Forecast Period | 2023 - 2033 |
| Estimated Market Value ( USD | $ 0.9 billion |
| Forecasted Market Value ( USD | $ 1.1 billion |
| Compound Annual Growth Rate | 1.9% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
